Tekmira Official Defends apoB as Cholesterol Target, Touts RNAi Rx Over Isis Antisense Candidate

Tekmira also released its second-quarter financial results, posting decreased losses on higher revenues.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.